文献速递肿瘤 PET/CT

68Ga-PSMA-11 PET/CT 用于新诊断前列腺腺癌

68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
PubMed 文献 · Clin Nucl Med · 2018-01-01

该研究回顾性分析 78 例活检证实的前列腺癌患者,评估 68Ga-PSMA-11 PET/CT 在初诊分期中的价值。结果显示 40 例(51.2%)发现转移,44 例(56.4%)分期较常规影像改变;原发灶 SUVmax 与 Gleason 评分、转移范围及 PSA 水平相关。

要点

  • 68Ga-PSMA-11 PET/CT 在 51.2% 初诊患者中检出转移。
  • 56.4% 患者分期较常规影像发生改变。
  • 原发灶 SUVmax 与 Gleason 评分、转移范围及 PSA 水平相关。

核心结论

  • 68Ga-PSMA-11 PET/CT 是新诊断前列腺癌初始评估的重要影像方法,可显著改变疾病分期;原发灶 SUVmax 与 Gleason 评分、转移范围及 PSA 水平相关,可定义预后。

研究设计与样本

  • 回顾性分析 78 例活检证实的前列腺癌患者,均行 68Ga-PSMA-11 PET/CT 用于初始分期,按 D'Amico 风险分层分组;所有患者行盆腔 MRI,65 例另行骨显像,比较 PET/CT 与常规影像的分期结果。

主要发现

  • 78 例中低危 5 例、中危 18 例、高危 55 例;68Ga-PSMA-11 PET/CT 检出转移 40 例(51.2%),其中区域淋巴结转移 10 例、远处转移 30 例。
  • 68Ga-PSMA-11 PET/CT 较常规影像改变 44 例(56.4%)的分期。
  • Gleason 评分 6 和 7 的肿瘤 SUVmax 与 Gleason 评分 8、9、10 的肿瘤 SUVmax 间差异有统计学意义(P = 0.003)。
  • 无转移患者(n = 38)与区域淋巴结转移或远处转移患者(n = 40)的 SUVmax 分别为 16.1 ± 10.9 与 28.7 ± 25.8,差异有统计学意义(P = 0.003)。
  • PSA < 10 ng/mL 患者与 PSA 10–<20 ng/mL 及 PSA ≥20 ng/mL 患者的 SUVmax 间差异有统计学意义(P = 0.009);PSA 与原发灶 SUVmax 呈弱相关(r = 0.21)。

临床怎么用

  • 对于新诊断前列腺癌患者,68Ga-PSMA-11 PET/CT 可用于初始分期评估,较常规影像可改变相当比例患者的分期。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Prostate-specific membrane antigen (PSMA) ligand PET/CT is an emerging modality to detect the metastatic disease, especially in intermediate- and high-risk prostate cancer (PCa). In this study, we analyzed the contribution of Ga-PSMA-11 PET/CT in staging and therapy management of newly diagnosed PCa. MATERIALS AND METHODS: A total of 78 patients with biopsy-proven PCa who were referred for Ga-PSMA-11 PET/CT for primary staging were retrospectively analyzed. The patients were divided into risk groups according to the D'Amico risk stratification criteria. All of the patients had undergone pelvic MRI, and 65 patients had bone scintigraphy also. The findings of Ga-PSMA-11 PET/CT were compared with these conventional imaging (CI) methods for staging of the disease. The relations between SUVmax of the primary tumors and Gleason scores (GSs), prostate-specific antigen (PSA) levels, and metastatic extent of the disease were analyzed. RESULTS: Of 78 patients, 5 patients were in low-risk group, 18 patients were in intermediate-risk group, and 55 patients were in high-risk group. Metastatic disease was found in 40 (51.2%) of 78 patients in Ga-PSMA-11 PET/CT. Ten patients had regional lymph node metastases, and 30 patients had distant metastases. Ga-PSMA-11 PET/CT changed the staging in 44 (56.4%) of 78 patients compared with CI. There was significant difference between the SUVmax of the tumors with GSs of 6 and 7 compared with GSs of 8, 9, and 10 (P = 0.003). The SUVmax were significantly different between the patients with no metastasis (n = 38) and patients with regional lymph node metastases or distant metastases (n = 40; 16.1 ± 10.9, 28.7 ± 25.8, P = 0.003, respectively). There was significant difference between the SUVmax of patients with PSA level less than 10 ng/mL compared with patients with PSA level of 10 or greater and less than 20 ng/mL and PSA 20 ng/mL or greater (P = 0.009). A weak correlation between PSA and primary tumor SUVmax was also found (r = 0.21). CONCLUSIONS: Ga-PSMA-11 PET/CT is an important imaging modality for primary evaluation of newly diagnosed PCa changing the disease stage substantially. Also the SUVmax of the primary tumor has a relation with GS, metastatic extent of disease, and PSA levels defining the prognosis.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ergül N, Yilmaz Güneş B, Yücetaş U, et al. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma. Clin Nucl Med. 2018. PMID: 30273204. doi:10.1097/RLU.0000000000002289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。